To define the candidate OC patient groups that would benefit for PARP inhibitor therapies alone or in combination with antiangiogenic treatment, taking into consideration the genetic background, tumor biomarkers, and so on, should be one of the future research directions. The gene discussed is PARP1; the disease is neoplasm.